Genentech-Sangamo deal to advance neurodegenerative treatments
Overall, Sangamo Therapeutics will be eligible up to $1.9 billion…
Overall, Sangamo Therapeutics will be eligible up to $1.9 billion from Genentech, which includes various milestone and royalty payments.